cas 5762-40-3, 2,4-Dimethyl-4-nitrovaleric acid methyl ester

Articles about 5762-40-3Total 16 be found

PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
The disclosure provides processes for preparing a compound of Formula (I).
-
Paragraph 0483-0486

(2021/08/13)

SOLID FORMS OF MODULATORS OF CFTR
Crystalline and amorphous forms of a potassium salt of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
-
Paragraph 00242

(2020/10/27)

METHODS OF TREATMENT FOR CYSTIC FIBROSIS
This application describes methods of treating cystic fibrosis comprising administering Compound I:, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising any of the foregoing.
-
Paragraph 00194-00195

(2020/12/11)

COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS
Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.
-
Paragraph 00291; 00292; 00293; 00294

(2019/01/22)

METHODS OF TREATMENT FOR CYSTIC FIBROSIS
Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
-
Paragraph 00146-00147

(2019/02/06)

CRYSTALLINE FORMS OF MODULATORS OF CFTR
Crystalline Forms of Compound (I); crystalline Forms of Compound (II) and crystalline forms of pharmaceutically acceptable salts of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
-
Paragraph 00403

(2019/10/19)

PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
-
Paragraph 0515-0517

(2019/08/20)

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical composi
-
Paragraph 00158

(2019/10/29)

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.
-
Paragraph 00158

(2019/11/04)

CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereofare disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
-
Paragraph 0459; 0460; 0461

(2019/05/07)

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
-
Paragraph 00230; 00231; 00232

(2018/04/17)

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
-
Paragraph 00256-00259

(2018/06/30)

METHODS OF TREATMENT FOR CYSTIC FIBROSIS
Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.
-
Paragraph 00152; 00153

(2019/01/06)

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
Page/Page column 1193

(2021/02/10)

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
-
Paragraph 4512; 4513

(2016/05/02)

Perfluoroalkylation of the 2-Nitropropyl Anion. Evidence for an SRN1 Process
The reaction of primary perfluoroalkyl iodides (RfI, Rf = n-C6F13, n-C8F17) and diiodides I(CF2)nI (n=4,6) with the 2-nitropropyl anion gives 2-(perfluoroalkyl)-2-nitropropanes.The anion was employed as the tetrabutylammonium salt in benzene or in organic solvent /water mixtures or as the lithium salt in dimethylformamide or dimethyl sulfoxide with and without UV irradiation.Evidence is presented for an SRN1 process by trapping of radical intermediates with benzene, styrene, methyl methacrylate, and vinyl acetate and by competition experiments with p-dinitrobenzene.Substitution of the nitro group in the 2-(perfluoroalkyl)-2-nitropropanes occurs under SRN1 conditions with 2-nitropropyl anion, benzenethiolate, and hydride.
Feiring, Andrew E.
p. 347 - 354
(2007/10/02)